Healthcare Quality, Patient Safety & PolicyImmunityBio Discusses FDA Resubmission Path for ANKTIVA®Business WireJanuary 20, 2026January 21, 2026 by Business WireJanuary 20, 2026January 21, 2026031 ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it recently held a Type B End-of-Phase meeting with the U.S. FDA regarding the...
